1365173-21-2

Basic information

• Product Name: phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester
• Synonyms: phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester
• CAS NO: 1365173-21-2
• Molecular Weight: 649.61
• Mol File: 1365173-21-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester(1365173-21-2)
• EPA Substance Registry System: phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester(1365173-21-2)

Safety Data

• Hazardous Substances Data: 1365173-21-2(Hazardous Substances Data)

Upstream product

• 13086-84-5 di-tert-butyl phosphite 
• 1243706-25-3 2-chloro-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,7-dihydropurin-6-one 
• 1243708-11-3 6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-6,7-dihydro-1H-purine-2-carbonitrile 
• 229625-50-7 di-tert-butyl chloromethyl phosphate 
• 33494-81-4 phosphoric acid di-tert-butyl ester 
• 752222-88-1 1-(3-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxylic acid 
• 142665-13-2 5,6-diamino-3-propyluracil 

Downstream Products

• 1365172-79-7 phosphoric acid mono-{2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl}ester 

Relevant articles and documents

PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS

The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. Such conditions include, but are not limited to, asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders including inflammatory bowel disease, sickle cell disease, and/or autoimmune diseases, and to their use in treating mammals for various disease states, such as gastrointestinal disorders, immunological disorders, hypersensitivity disorders, neurological disorders, and cardiovascular diseases due to both cellular hyperproliferation and apoptosis, and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.